Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTOS: Canakinumab in Post-MI Patients
NCT01327846Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 40
01
Overview
A Phase 3 trial of canakinumab in atherosclerosis, sponsored by Novartis. Started Apr 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT01327846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01327846.